Yep. If you've been following the changes at the FDA an accelerated approval definitely a possibility in this one. The FDA is to its credit trying to improve the laboured process of its approvals in novel biologics for chronic illnesses where patients face a very poor prognosis under standard of care. Far too mnay amputations globally for DFU. This one is crying for out an AA.
CYP Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)